Anti-inflammatory strategies for the treatment of sepsis

Bibliography

• MUCKART DJ, BHAGWANJEE S: American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit. Care Med. (1997) 25(11):1789–1795.
   PubMed Web of Science ®Google Scholar
• ANGUS DC, LINDE-ZWIRBLE WT, LIDICKER J et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs ofcare. Crit. Care Med. (2001)29(7):1303–1310.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, VINCENT JL, LATERRE PF et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. J. Med. (2001) 344(10):699–709.
   PubMed Web of Science ®Google Scholar
• DAVIS CE, BROWN KR, DOUGLAS H, TATE WJ III, BRAUDE Al: Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin.Irranunel (1969) 102(3):563–572.
   Google Scholar
• COHEN J: Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br. Med. Bull. (1999) 55(1):212–225.
   PubMed Web of Science ®Google Scholar
• JIN H, YANG R, MARSTERS S et al.: Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J. Clin. Invest. (1995) 95(4):1947–1952.
   PubMed Web of Science ®Google Scholar
• RINTALA E, PEURAVUORI H, PULKKI K, VOIPIO-PULKKI LM, NEVALAINEN T: Bactericidal/ permeability-increasing protein (BPI) insepsis correlates with the severity of sepsisand the outcome. Intensive Care Med.(2000) 26(9):1248–1251.
   PubMed Web of Science ®Google Scholar
• LEVIN M, QUINT PA, GOLDSTEIN B et al.: Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet (2000) 356(9234):961–967.
   Google Scholar
• SUZUKI H, NEMOTO H, NAKAMOTO H et al.: Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther. Apher. (2002) 6(3):234–240.
   PubMedGoogle Scholar
• NEMOTO H, NAKAMOTO H, OKADA H et al.: Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Puril (2001) 19(4):361–368; Discussion:368–369.
   Google Scholar
• HANASAWA K: Extracorporeal treatment for septic patients: new adsorption technologies and their clinical application. Ther. Apher. (2002) 6(4):290–295.
   PubMedGoogle Scholar
• MICHIE HR, SPRIGGS DR, MANOGUE KR et al: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 104(2):280–286.
   PubMed Web of Science ®Google Scholar
• MICHIE HR, MANOGUE KR, SPRIGGS DR et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl. J. Med. (1988) 318(23):1481–1486.
   PubMed Web of Science ®Google Scholar
• TRACEY KJ, BEUTLER B, LOWRY SF et al.: Shock and tissue injury induced by recombinant human cachectin. Science (1986) 234(4775):470–474.
   PubMed Web of Science ®Google Scholar
• TRACEY KJ, FONG Y, HESSE DG et al.: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1987) 330(6149):662–664.
   PubMed Web of Science ®Google Scholar
• REINHART K, KARZAI W: Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Grit. Care Med. (2001) 29\(Suppl. 7):5121–5125.
   Google Scholar
• ARNDT P, ABRAHAM E: Immunological therapy of sepsis: experimental therapies. Intensive Care Med. (2001)27\(Suppl. 1):5104–5115.
   Google Scholar
• REINHART K, MENGES T, GARDLUND B et al.: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragmentafelimomab in hyperinflammatory response during severe sepsis: the RAMSES study.Crit. Care Med. (2001) 29(4):765–769.
   Google Scholar
• OKUSAWA S, GELFAND JA, IKEJIMA T, CONNOLLY RJ, DINARELLO CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.j Clin. Invest. (1988) 81(4):1162–1172.
   Google Scholar
• WAKABAYASHI G, GELFAND JA, BURKE JF, THOMPSON RC, DINARELLO CA: A specific receptor antagonist for interleukin 1 prevents Escherichia coil-induced shock in rabbits. FASEB J. (1991) 5(3):338–343.
   PubMed Web of Science ®Google Scholar
• OHLSSON K, BJORK P, BERGENFELDT M, HAGEMAN R, THOMPSON RC: Interleuldn-1 receptor antagonist reduces mortality from endotoxin shock. Nature (1990) 348(6301):550–552.
   PubMed Web of Science ®Google Scholar
• FISCHER E, MARANO MA, VAN ZEE KJ et al.: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coliseptic shock, but fails to alter host responses to sublethal endotoxemia. Clin. Invest. (1992) 89(5):1551–1557.
   Google Scholar
• OPAL SM, FISHER CJ JR, DHAINAUT JF et al.: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med (1997) 25(7):1115–1124.
   Google Scholar
• FISHER CJ JR, DHAINAUT JF, OPAL SM et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL- lra Sepsis Syndrome Study Group. JAMA (1994) 271(23):1836–1843.
   Google Scholar
• FINK MP: Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis." Antimicrob. Cheinother. (1998) 41(Suppl. A):81–94.
   Google Scholar
• LOPEZ DIEZ F, NIETO ML, FERNANDEZ-GALLARDO S, GIJON MA, SANCHEZ CRESPO M: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.Clin. Invest. (1989) 83(5):1733–1740.
   Google Scholar
• VADAS P: Elevated plasma phospholipase A2 levels: correlation with thehemodynamic and pulmonary changes in gram-negative septic shock. J. Lab. Clin. Med. (1984) 104(6):873–881.
   PubMed Web of Science ®Google Scholar
• VINCENT JL, SPAPEN H, BAKKER J, WEBSTER NR, CURTIS L: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit. Care Med. (2000) 28(3):638–642.
   PubMed Web of Science ®Google Scholar
• DHAINAUT JF, TENAILLON A, HEMMER M et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Grit. Care Med. (1998) 26(12):1963–1971.
   Google Scholar
• DHAINAUT JF, TENAILLON A, LE TULZO Y et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Grit. Care Med. (1994) 22(11) :1720–1728.
   Google Scholar
• FEIN AM, BERNARD GR, CRINER GJ et al.: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA (1997) 277(6):482–487.
   Google Scholar
• BONE RC, SLOTMAN G, MAUNDER R et al.: Randomized double-blind, multicenter study of prostaglandin El in patients with the adult respiratory distress syndrome. Prostaglandin El Study Group. Chest (1989) 96(1):114–119.
   Google Scholar
• ABRAHAM E, PARK YC, COVINGTON P, CONRAD SA, SCHWARTZ M: Liposomal prostaglandin El in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit. Care Med. (1996) 24(1):10–15.
   PubMed Web of Science ®Google Scholar
• VINCENT JL, BRASE R, SANTMAN F et al: A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin El (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. (2001) 27(10):1578–1583.
   PubMed Web of Science ®Google Scholar
• YU M, TOMASA G: A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adultrespiratory distress syndrome. Crit. Care Med. (1993) 21(11):1635–1642.
   PubMed Web of Science ®Google Scholar
• AUTHORS FOR THE ARDS NETWORK: Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. "AMA (2000) 283(15):1995–2002.
   Google Scholar
• HAUPT MT, JASTREMSKI MS, CLEMMER TP, METZ CA, GORIS GB: Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit. Care Med. (1991) 19(11):1339–1347.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, REINES HD, HALUSHKA PV et al.: Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. Am. Rev. Respir. Dis. (1991) 144(5):1095–1101.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, WHEELER AP, RUSSELL JA et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl. J. Med. (1997) 336(13):912–918.
   PubMed Web of Science ®Google Scholar
• KNOFERL MW, DIODATO MD, SCHWACHA MG, CIOFFI WG, BLAND KI, CHAUDRY IH: Cyclooxygenase-2-mediated regulation of Kupffer cell interleukin-6 production following trauma-hemorrhage and subsequent sepsis. Shock (2001) 16:479–483.
   PubMed Web of Science ®Google Scholar
• REDDY RC, CHEN GH, TATEDA K et al.: Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am." Physiol Lung Cell Mol Physiol (2001) 281:L537–L543.
   Google Scholar
• AGUSTI AG, TO GORES B, IBANEZ J et al.: Effects of N-acetylcysteine on tissue oxygenation in patients with multiple organ failure and evidence of tissue hypwda. Eur. Respir J(1997) 10(9):1962–1966.
   PubMed Web of Science ®Google Scholar
• PEAKE SL, MORAN JL, LEPPARD PI: N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Crit. Care Med. (1996) 24(8):1302–1310.
   PubMed Web of Science ®Google Scholar
• SPIES CD, REINHART K, WITT I et al.: Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit. Care Med. (1994) 22(11):1738–1746.
   PubMed Web of Science ®Google Scholar
• GALLEY HF, HOWDLE PD, WALKER BE, WEBSTER NR: The effects of intravenous antioxidants in patients with septic shock. Free Rad. Biol. Med. (1997) 23(5):768–774.
   PubMed Web of Science ®Google Scholar
• FORCE VILLE X, VITOUX D, GAUZIT R, COMBES A, LAHILAIRE P, CHAPPUIS P: Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Grit. Care Med. (1998) 26(9):1536–1544.
   PubMed Web of Science ®Google Scholar
• ANGST WURM MW, SCHOTTDORF J, SCHOPOHL J, GAERTNER R: Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Grit. Care Med. (1999) 27(9):1807–1813.
   PubMed Web of Science ®Google Scholar
• JOHNSON ML, BILLIAR TR: Roles of nitric oxide in surgical infection and sepsis. World J. Surg. (1998) 22(2):187–196.
   PubMed Web of Science ®Google Scholar
• GOMEZ-JIMENEZ J, SALGADO A, MOURELLE M et al: L-arginine: nitric oxide pathway in endotoxemia and human septic shock. Crit. Care Med. (1995) 23(2):253–258.
   PubMed Web of Science ®Google Scholar
• GROENEVELD PH, KWAPPENBERG KM, LANGERMANS JA, NIBBERING PH, CURTIS L: Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. Intensive Care Med. (1996) 22(11):1197–1202.
   PubMed Web of Science ®Google Scholar
• AVONTUUR JA, BIEWENGA M, BUIJK SL, KANHAI KJ, BRUINING HA: Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock. Shock (1998) 9(6):451–454.
   PubMed Web of Science ®Google Scholar
• AVONTUUR JA, TUTEIN NOLTHENIUS RP, VAN BODEGOM JW, BRUINING HA: Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit. Care Med. (1998) 26(4):660–667.
   PubMed Web of Science ®Google Scholar
• LORENTE JA, LANDIN L, DE PABLO R, RENES E, LISTE D: L-arginine pathway in the sepsis syndrome.Grit. Care Med. (1993) 21:1287–1295.
   PubMed Web of Science ®Google Scholar
• SCHILLING J, CAKMAKCI M, BATTIG U, GEROULANOS S: A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase. Intensive Care Med (1993) 19:227–231.
   PubMed Web of Science ®Google Scholar
• PETROS A, LAMB G, LEONE A, MONCADA S, BENNETT D, VALLANCE P: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. (1994) 28(1):34–39.
   PubMed Web of Science ®Google Scholar
• KEANEY JF JR, PUYANA JC, FRANCIS S, LOS CALZO JF, STAMLER JS, LOSCALZO J: Methylene blue reverses endotoxin-induced hypotension. Circ. Res. (1994) 74(6):1121–1125.
   PubMed Web of Science ®Google Scholar
• GACHOT B, BEDOS JP, VEBER B, WOLFF M, REGNIER B: Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. (1995) 21(12):1027–1031.
   PubMed Web of Science ®Google Scholar
• DAEMEN-GUBBELS CR, GROENEVELD PH, GROENEVELD AB, VAN KAMP GJ, BRONSVELD W, THUS LG: Methylene blue increases myocardial function in septic shock. Grit. Care Med. (1995) 23(8):1363–1370.
   PubMed Web of Science ®Google Scholar
• PREISER JC, LEJEUNE P, ROMAN A et al.: Methylene blue administration in septic shock: a clinical trial. Crit. Care Med. (1995) 23(2):259–264.
   PubMed Web of Science ®Google Scholar
• KIROV MY, EVGENOV OV, EVGENOV NV et al.: Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit. Care Med. (2001) 29(10):1860–1867.
   PubMed Web of Science ®Google Scholar
• PRIVALLE C, TALARICO T, KENG T, DEANGELO J: Pyridoxalated hemoglobin polyoxyethylene: a nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock. Free Radic. Biol. Med (2000) 28(10):1507–1517.
   PubMed Web of Science ®Google Scholar
• BONE HG, WAURICK R, VAN AKEN H, BOOKE M, PRIEN T, MEYER J: Comparison of the haemodynamic effects of nitric oxide synthase inhibition and nitric oxide scavenging in endotoxaemic sheep. Intensive Care Med. (1998) 24(1):48–54.
   PubMed Web of Science ®Google Scholar
• SCHADE UF, VON DER BOSCH J, SCHONHARTING M: Pentoxifylline increases survival of mice in endotoxic shock. Prog. Clin. Biol. Res. (1989) 301:223–227.
   PubMedGoogle Scholar
• STAUBACH KH, SCHRODER J, STUBER F, GEHRKE K, TRAUMANN E, ZABEL P: Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch. Surg. (1998) 133(1):94–100.
   PubMed Web of Science ®Google Scholar
• ZENI F, PAIN P, VINDIMIAN M et al.: Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit. Care Med. (1996) 24(2):207–214.
   PubMed Web of Science ®Google Scholar
• BACHER A, MAYER N, KLIMSCHA W, OISMULLER C, STELTZER H, HAMMERLE A: Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit. Care Med. (1997) 25(5):795–800.
   PubMed Web of Science ®Google Scholar
• LAUTERBACH R, PAWLIK D, KOWALCZYK D, KSYCINSKI W, HELWICH E, ZEMBALA M: Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Grit. Care Med. (1999) 27(4):807–814.
   PubMed Web of Science ®Google Scholar
• NUIJENS JH, EERENBERG-BELMER AJ, HUUBREGTS CC et al.: Proteolytic inactivation of plasma Cl-inhibitor in sepsis. Clin. Invest. (1989) 84(2):443–450.
   Google Scholar
• FRONHOFFS S, LUYKEN J, STEUER K, HANSIS M, VETTER H, WALGER P: The effect of Cl-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Med (2000) 26(10):1566–1570.
   PubMed Web of Science ®Google Scholar
• HACK CE, OGILVIE AC, EISELE B, JANSEN PM, WAGSTAFF J, THUS LG: Initial studies on the administration of Cl-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Frog. Clin. Biol. Res. (1994) 388:335–357.
   PubMedGoogle Scholar
• BENNETT IL, FINLAND M, HAMBORGER M, KASS EH, LEPPER M, WEISBREN BA: The effectiveness of hydrocortisone in the management of severe infection. JAMA (1963) 183:462–465.
   Web of Science ®Google Scholar
• BRIEGEL J, FORST H, HALLER Met al: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med. (1999) 27(4):723–732.
   PubMed Web of Science ®Google Scholar
• ANNANE D, SEBILLE V, CHARPENTIER C et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 288(7):862–871.
   PubMed Web of Science ®Google Scholar
• KAUL R, MCGEER A, NORRBY-TEGLUND A et al: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. (1999) 28(4):800–807.
   PubMed Web of Science ®Google Scholar
• SHENOI A, NAGESH NK, MAIYA PP, BHAT SR, SUBBA RAO SD: Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediam. (1999) 36(11):1113–1118.
   PubMedGoogle Scholar
• ALEJANDRIA MM, LANSANG MA, DANS LF, MANTARING JB: Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst. Rev. (2002) 1:CD001090.
   Google Scholar
• VOLK HD, REINKE P, KRAUSCH D et al.: Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med. (1996)22 (Suppl. 10:5474–5481.
   Google Scholar
• DOCKE WD, RANDOW F, SYRBE U et al.: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. (1997) 3(6):678–681.
   PubMed Web of Science ®Google Scholar
• GORGEN I, HARTUNG T, LEIST M et al.: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J. Immunol (1992) 149(3):918–924.
   PubMed Web of Science ®Google Scholar
• O'REILLY M, SILVER GM, GREENHALGH DG, GAMELLI RL, DAVIS JH, HEBERT JC: Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. Trauma (1992) 33(5):679–682.
   PubMed Web of Science ®Google Scholar
• ARSLAN E, YAVUZ M, DALAY C: The relationship between tumor necrosis factor (TNF)-alpha and survival following granulocyte-colony stimulating factor (G-CSF) administration in burn sepsis. Burns (2000) 26(6):521–524.
   PubMed Web of Science ®Google Scholar
• WUNDERINK R, LEEPER K JR, SCHEIN R et al: Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest (2001) 119(2):523–529.
   PubMed Web of Science ®Google Scholar
• VINCENT JL, SUN Q, DUBOIS MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. (2002) 34(8):1084–1093.
   PubMed Web of Science ®Google Scholar
• DROSSOU-AGAKIDOU V, KANAKOUDI-TSAKALIDOU F,SARAFIDIS K et al.: In vivo effect of rhGM-CSF and rhG-CSF on monocyte HLA-DR expression of septic neonates. Cytokine (2002) 18(5):260.
   Google Scholar
• BILGIN K, YARAMIS A, HASPOLAT K, TAS MA, GUNBEY S, DERMAN 0: A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics (2001) 107(1):36–41.
   PubMed Web of Science ®Google Scholar
• PRESNEILL JJ, HARRIS T,STEWART AG, CADE JF, WILSON JVV: A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir: Crit. Care Med. (2002) 166(2):138–143.
   PubMed Web of Science ®Google Scholar
• CISNEROS RL, GIBSON FC,TZIANABOS AO: Passive transfer of poly-(1-6)-beta-glucotriosyl- (1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis. Infect. Immun. (1996) 64(6):2201–2205.
   PubMed Web of Science ®Google Scholar
• DELLINGER EP, BABINEAU TJ, BLEICHER P: Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch. Surg. (1999) 134:977–983.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN G, JANKOWSKI S, SHAHLA M et al.: Administration of an antibody to E-selectin in patients with septic shock. Crit. Care Med. (1996) 24(2):229–233.
   PubMed Web of Science ®Google Scholar
• CARRAWAY MS, WELTY-WOLF KE, KANTROW SP et al.: Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons. Am. J. Respir: Grit. Care Med. (1998)157(3 Pt 1):938–949.
   Google Scholar
• CREASEY AA, CHANG AC, FEIGEN L, WUN TC, TAYLOR FB JR,HINSHAW LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Gin. Invest. (1993) 91(6):2850–2856.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB JR, CHANG A, RUF W et al.: Lethal E coliseptic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock (1991) 33(3):127–134.
   PubMedGoogle Scholar
• TAYLOR FB JR, CHANG AC, PEER GT et al: DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shockor organ damage. Blood (1991) 78(2):364–368.
   PubMed Web of Science ®Google Scholar
• OPAL SM, PALARDY JE, PAREJO NA,CREASEY AA: The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit. Care Med. (2001) 29(1):13–17.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, REINHART K, SVOBODA P et al.: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Grit. Care Med (2001) 29:2081–2089.
   PubMed Web of Science ®Google Scholar
• DICKNEITE G: Antithrombin III in animal models of sepsis and organ failure. Semin. Thromb. Hemost. (1998) 24(1):61–69.
   PubMed Web of Science ®Google Scholar
• FOURRIER F, JOURDAIN M, TOURNOYS A: Clinical trial results with antithrombin III in sepsis. Grit. Care Med (2000) 28\(Suppl. 9):S38–S43.
   Google Scholar
• EISELE B, LAMY M, THUS LG et al.: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med (1998) 24(7):663–672.
   Google Scholar
• WARREN BL, EID A, SINGER P et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA (2001) 286(15):1869–1878.
   Google Scholar
• HEALY DP: New and emerging therapies for sepsis. Ann. Pliarmacother. (2002) 36(4):648–654.
   PubMed Web of Science ®Google Scholar
• RIEWALD M, PETROVAN RJ, DONNER A, MUELLER BM, RUF W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science (2002) 296(5574):1880–1882.
   PubMed Web of Science ®Google Scholar
• WARREN HS, SUFFREDINI AF, EICHACKER PQ, MUNFORD RS: Risks and benefits of activated protein C treatment for severe sepsis. N Engl. J. Med. (2002) 347:1027–1030.
   PubMed Web of Science ®Google Scholar
• EICHACKER PQ, PARENT C, KALIL A et al.: Risk and the efficacy ofantiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. Respir. Grit. Care Med. (2002) 166(9):1197–1205.
   PubMed Web of Science ®Google Scholar
• WANG H, BLOOM 0, ZHANG M et al: HMG-1 as a late mediator of endotwdn lethality in mice. Science (1999) 285(5425):248–251.
   PubMed Web of Science ®Google Scholar
• CZERNIAK BJ, SARNIA V, PIERSON CL et al: Protective effects of C5a blockade in sepsis. Nat. Med (1999) 5(7):788–792.
   PubMed Web of Science ®Google Scholar
• RIEDEMANN NC, GUO RF, NEFF TA et al: Increased C5a receptor expression in sepsis. Clin. Invest. (2002) 110(1):101–108.
   Google Scholar
• CALANDRA T, ECHTENACHER B, ROY DL et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. (2000) 6(2):164–170.Ha ROGER T, DAVID J, GLAUSER MP, CALANDRA T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2001) 414(6866):920–924.
   Google Scholar
• HOTCHKISS RS, CHANG KC, SWANSON PE et al: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol (2000) 1(6):496–501.
   PubMed Web of Science ®Google Scholar
• HOTCHKISS RS, TINSLEY KW, SWANSON PE et al: Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Nati Acad. Sci. USA (1999) 96(25):14541–14546.
   PubMed Web of Science ®Google Scholar
• OBERHOLZER C, OBERHOLZER A, CLARE-SALZLER M, MOLDAWER LL: Apoptosis in sepsis: a new target for therapeutic exploration. FASEB (2001) 15(6):879–892.
   PubMed Web of Science ®Google Scholar